ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HIK Hikma Pharmaceuticals Plc

1,935.00
0.00 (0.00%)
20 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1,935.00 1,927.00 1,929.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.88B 192M 0.8653 22.36 4.29B
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,935p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,750.00p to 2,165.00p.

Hikma Pharmaceuticals currently has 221,886,453 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4.29 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 22.36.

Hikma Pharmaceuticals Share Discussion Threads

Showing 326 to 348 of 1875 messages
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
22/4/2016
16:37
Am surprised how few post for this share but again today up even when market down a lot. This year is going to be an interesting ride next few months as if reach 26 not sure what to do hold for the long term or take the gains as already nearly 30% up
mrthomas
21/4/2016
16:48
30 days of straight gains?? topslice??
r ball
16/4/2016
18:47
Roxane acquisition and boehringer seat on the board.
r ball
16/4/2016
17:35
come on don,t leave me in the dark what's a boeringer synergy
ali47fish
16/4/2016
16:41
is it my boehringer synergy??
r ball
16/4/2016
11:43
the rise is because the directors have been buying and i think as a bid target when dfizer had to abandon the bid for allergan because of new rules in Us about taxation. i am still watching it to add more
ali47fish
16/4/2016
10:57
why the rise? now not ftse 100?
r ball
11/4/2016
08:48
It has a compelling growth story.

Continuing towards those highs.

broadwood
10/4/2016
19:42
ftse100 is kiss of death. would performance improve once m East settles down. thinking of buying chg to counter risk
r ball
08/4/2016
09:37
Held this share for just over a month and its been a real roller coaster. But having said that it could be a long term hold less see. Think that it could end up in the FTS 100 again at the end of this quarter in June that being the case the price will go up even higher.

management buying at that level is a good sign as well

mrthomas
08/4/2016
08:05
Hikma Pharmaceuticals said on Friday that its abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder has been accepted for filing by the Food and Drug Administration in the US.
The product is the generic version of GlaxoSmithKline's Advair Diskus, which is indicated for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

It is delivered using Vectura's proprietary dry powder inhaler and formulation technology.

Chief executive officer Said Darwazah said: "We are very pleased to have achieved this important milestone in the development of generic Advair Diskus. With our partner, Vectura, our team has worked closely with the FDA to ensure the quality of the ANDA submission.

"Our interactions with the FDA have helped clarify the requirements for the development of a robust, patient friendly, (AB-rated) substitutable generic product for Advair Diskus. We look forward to bringing to market this very important product for patients."

broadwood
08/4/2016
06:18
Great news.

Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today confirms that its abbreviated new drug application (ANDA) for fluticasone propionate and salmeterol inhalation powder has been accepted for filing by the U.S. Food and Drug Administration (

broadwood
07/4/2016
15:09
what prompted the big turnaround today and like a one day reversal in charting terminology ? Ok,Dow falling and a bad market but it ignored that the other day ! R ball - that pullback did happen today !
arja
06/4/2016
09:14
That's a pretty big commitment in anyones book. Share price continues to recover and this news certainly helps.
broadwood
05/4/2016
17:39
The chairman and chief executive of Hikma Pharmaceuticals has purchased more than £600,000 worth of shares in the drugmaker.
Said Darwazah bought 30,000 shares for 2,055.00p each, totalling £616,499.98

JP Morgan on Wednesday reiterated its 'overweight' rating on the stock and set a target price of 2,300p, saying it believes there is a possible 13.5% upside from the opening price of 2,027p

broadwood
05/4/2016
15:09
If you wait for a pullback it never happens. buy and strength and increase holding as share price rises.
r ball
05/4/2016
11:23
amazing how some stocks such as this one powers ahead onn a rally bad day in market and with dow futures falling . Just wish I had some but maybe still time on a pullback ! Good luck to those holding stock or a long open position .
arja
17/3/2016
10:24
Oh indeed, indeed.
3rd eye
17/3/2016
09:05
Still benefitting from that encouraging outlook.
broadwood
16/3/2016
16:55
From the FAR9 thread...........

HIK Hikma Pharma

Goes to the top of my red hot watch list after results today.





Broker Cantor

Revenue performance largely in line – Having provided a trading statement in November last year which detailed revenue and margin expectations, an inline performance in terms of todays reported numbers is hardly surprising. Injectables revenues of $710 (+3% CER%), was slightly ahead of our expectations of $699m with an adjusted operating margin of 44%. Revenue in the Branded business, driven by a recovery in Algeria, strong growth in Egypt and good demand in Saudi Arabia as well as other gulf states, was $570m (+13% CER) versus our forecast of $579m accompanies by a modest improvement in the adjusted operating margin of 3.9% (at CER). Lastly Generics delivered revenue of $151m (-30%) compared to our forecast of $151m at a respectable adjusted operating margin of 30.5%, albeit down from the heady supranormal margins this division has enjoyed over the past couple of years. Overall EPSA of 143.7c (-5%) is ahead of our forecast of $1.28 and consensus of 1.34 helped by a better than expected injectables margin.

· Guidance for 2016 – Hikma has provided revenue guidance of $2.0-$2.1bn which compares to our forecast of $2.043bn and consensus of $2.12bn. Guidance for the key injectables division suggests growth of mid to high single digits compared to our forecast of double digit growth although the forecast of a 36% adjusted operating margin is ahead of our forecast of 32%. The combined generics business is expected to deliver sales in the range of $640m to $670m which is ahead of our forecast of $614m suggesting that the mix may favour the traditional generics business over Injectables compared to our initial expectation. Elsewhere the Branded business is guided to perform in line with historical trends.

· Generic powerhouse – Mainly through a process of organic growth and timely acquisitions Hikma has grown its injectables and non-injectables generic businesses. The injectables business in particular has delivered stunning growth as it has sought to satisfy the demand for products which have suffered from acute shortages in the US. As a consequence, the division has delivered supra-normal profitability which has remained at significantly higher levels for longer than we expected. Although near term growth will be subdued, the addition of Bedford Labs should reinvigorate growth from 2016 onwards.

· Non-injectables enjoying a better outlook – Although at one time our hope was that Hikma would divest this once troubled business, the acquisition of Roxane should provide greater scale as well as access to a portfolio of marketed generic products and a pipeline of generic drug applications; positioning Hikma in the higher echelons of the US generic drug market. The recent disclosure of lower than anticipated 2015 sales here has little bearing on this view longer term.

· Attractive entry point – Hikma currently trades on a prospective 2017E PE of 15.3*x based on our proforma forecasts, this multiple drops to 12.8x by 2018E which for a company offering high quality double digit earnings growth and a strong market position in its chosen market segments looks inexpensive. Our DCF employing a calculated WACC of 8.5%, derives an NPV of 2300p. We reiterate our BUY recommendation and TP of 2300p.

· Risks – Operating its injectable and oral generics business predominantly in the US, Hikma remains exposed to pricing pressure in this market. However, we believe recent attention in this area to be largely political posturing ahead of the upcoming US Presidential elections. Additionally, the generics market is generally seen to be highly competitive having had 30+ years to settle into the Drug Price Competition and Patent Term Restoration Act (Hatch Waxman) and with Hikma’s direction of travel away from relying on wind fall profits from market shortages, we see this risk diminishing as time passes.

Summary

HIK LN (1721p, TP 2300p), Market Cap: £4,119m
Our View: 2015 revenue performance largely in line with our and market consensus, with earnings ahead. 2016E revenue guidance also in line with our own forecasts although mix slightly different with generics business slightly ahead and injectables contributing a bit less, but at a higher margin than we forecasts. Of more relevance to the long term investment case is the Roxane acquisition which should be a transformational for this underperforming business. Roxane should allow Hikma to compete with greater scale and without the need for “specific market opportunities”. Offering high quality earnings growth and a strong market position in its chosen arenas Hikma currently looks inexpensive to us, and we reiterate our Buy recommendation and target price of 2300p.

3rd eye
16/3/2016
16:12
Roxane. headline figs. dire esp generics
r ball
16/3/2016
15:46
absolutely broadwood- where is everybody here- do you know why the turnarounf and why to read into it?
ali47fish
16/3/2016
15:36
What a turnaround in the price today.
broadwood
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older

Your Recent History

Delayed Upgrade Clock